Orgenesis
Germantown, US · Nevada corporation · 1 known investors
Orgenesis operates the POCare Platform for developing, scaling, and commercializing advanced cell and gene therapies delivered at the point of care. It works with academia, research institutes, and hospitals to bring these therapies to patients globally.
BiotechHealthtechMedical Devices
Founders & leadership
NR
Neil ReithingerExecutive
VC
Vered CaplanExecutive
FF
Ferber FerberExecutive
JT
Joseph TenneNamed on SEC filing
SF
Sarah FerberNamed on SEC filing
GY
Guy YachinNamed on SEC filing
Board
DS
EH
Etti HanochiBoard director
YA
Yaron AdlerBoard director
YY
Yachin YachinBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$33.9M disclosed across 7 rounds · 2014–2024
▶$2.3MraisedMar 2024 · 46 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2024 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mario PhilipsDirector
- David SidranskyDirector
- Ashish NandaDirector
- Guy YachinDirector
- Vered CaplanExecutive Officer, Director
- Victor MillerExecutive Officer
- Yaron AdlerDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Mar 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vered CaplanExecutive Officer, Director
- Yaron AdlerDirector
- Guy YachinDirector
- Mario PhilipsDirector
- Elliot MaltzExecutive Officer
- David SidranskyDirector
- Ashish NandaDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Aug 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$14.8MraisedApr 2022 · 2 investors · BiotechnologyRule 506(b)
▶$14.8MraisedApr 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mario PhilipsDirector
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Guy YachinDirector
- David SidranskyDirector
- Yaron AdlerDirector
- Ashish NandaDirector
- Offering amount
- $14.8M
- Amount sold
- $14.8M
- First sale
- Mar 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$9.2MraisedJan 2020 · 5 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJan 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Sarah FerberExecutive Officer
- Darren HeadExecutive Officer
- Dennis BedoretExecutive Officer
- Guy YachinDirector
- David SidranskyExecutive Officer
- Mario PhilipsDirector
- Ashish NandaExecutive Officer, Director
- Yaron AdlerExecutive Officer
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- Sales commissions
- $739.2K
- Placement agents
- Bean Capital Limited
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.2MraisedFeb 2018 · 16 investors · BiotechnologyRule 506(b)
▶$1.2MraisedFeb 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil ReithingerExecutive Officer
- Guy YachinDirector
- Ferber FerberExecutive Officer
- Ashish NandaDirector
- Vered CaplanExecutive Officer, Director
- Yaron AdlerDirector
- David SidranskyDirector
- Hugues BultotDirector
- Amount sold
- $1.2M
- Sales commissions
- $60K
- Placement agents
- Phoenix Financial Inc.
- First sale
- Jan 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.3MraisedDec 2015 · 10 investors · BiotechnologyRule 506(b)
▶$5.3MraisedDec 2015 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SidranskyDirector
- Etti HanochiDirector
- Yaron AdlerDirector
- Yachin YachinDirector
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Ferber FerberExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5.3M
- First sale
- Dec 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$24KraisedJul 2014 · 1 investors · BiotechnologyRule 506(c)
▶$24KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Vered CaplanExecutive Officer, Director
- Etti HanochiDirector
- Joseph TenneExecutive Officer
- David SidranskyDirector
- Sarah FerberExecutive Officer
- Yaron AdlerDirector
- Guy YachinDirector
- Offering amount
- $24K
- Amount sold
- $24K
- First sale
- Jul 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
eGenesis32 shared keywordseGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
Organogenesis31 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Genesis Molecular AI19 shared keywordsGenesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Orgenesis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Orgenesis do?
- Orgenesis operates the POCare Platform for developing, scaling, and commercializing advanced cell and gene therapies delivered at the point of care. It works with academia, research institutes, and hospitals to bring these therapies to patients globally.
- Who are Orgenesis's investors?
- Orgenesis's investors include Israel Biotech Fund.
- How much funding has Orgenesis raised?
- Orgenesis has disclosed $33.9M raised across 7 rounds.
- Where is Orgenesis headquartered?
- Orgenesis is headquartered in Germantown, US.